%0 Journal Article
%A Calle Rubio, Myrian
%A Rodríguez Hermosa, Juan Luis
%A Torres, Juan P. de
%A Marín, José María
%A Martínez-González, Cristina
%A Fuster, Antonia
%A Cosío, Borja G.
%A Peces-Barba, Germán
%A Solanes, Ingrid, Jose Luis
%A Feu-Collado, Nuria
%A Lopez-Campos, José Luis
%A Casanova, Ciro
%T COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort
%D 2021
%@ 1465-993X
%U https://hdl.handle.net/20.500.14352/98348
%X 134 patients (16.8%) were considered persistently controlled, 248 (31.1%) persistently uncontrolled and 416 (52.1%) changed control status during follow-up. The variables significantly associated with persistent control were not requiring triple therapy at baseline and having a better quality of life. Annual changes in outcomes (health status, psychological status, airflow limitation) did not differ in patients, regardless of clinical control status. All-cause mortality was lower in persistently controlled patients (5.5% versus 19.1%, p = 0.001). The hazard ratio for all-cause mortality was 2.274 (95% CI 1.394–3.708; p = 0.001). Regarding pharmacological treatment, triple inhaled therapy was the most common option in persistently uncontrolled patients (72.2%). Patients with persistent disease control more frequently used bronchodilators for monotherapy (53%) at recruitment, although by the end of the follow-up period, 20% had scaled up their treatment, with triple therapy being the most frequent therapeutic pattern.
%~